Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
Last trade$60.85
Day change-$2.085 (-3.31%)
Day range$60.70 – $63.20
Volume8,842,951
Market cap$128.63B
OpenXNYS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$128.63B
Price / earnings
13.86×
Price / book
5.76×
Price / sales
2.62×
EV / sales
3.31×
EV / EBITDA
10.94×
Profitability
Earnings per share
$4.54
Return on assets
10.59%
Return on equity
41.59%
Dividend yield
3.96%
Liquidity and leverage
Debt / equity
1.93×
Current ratio
1.53×
Quick ratio
1.38×
Cash ratio
0.47×
Cash flow
Price / cash flow
10.06×
Price / free cash flow
11.24×
Free cash flow
$11.44B
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for BMY, quarterly periods
Line item
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Q3 FY2024 Sep 30, 2024
Revenue
$12.97B
$11.49B
$12.5B
$12.22B
$12.27B
$11.2B
$12.34B
$11.89B
Cost of revenue
$3.73B
$3.42B
$4.1B
$3.44B
$3.37B
$3.03B
$4.81B
$2.96B
Gross profit
$9.25B
$8.07B
$8.41B
$8.79B
$8.9B
$8.17B
$7.53B
$8.94B
Selling, general and administrative
$1.83B
$1.62B
$2.18B
$1.79B
$1.71B
$1.58B
$2.14B
$1.98B
Research and development
$2.96B
$2.74B
$3.98B
$3.16B
$2.58B
$2.45B
$3.22B
$2.64B
Total operating expenses
$5.22B
$4.8B
$6.99B
$5.78B
$6.63B
$4.86B
$7.05B
$7.03B
Operating income
$4.03B
$3.27B
$1.42B
$3.01B
$2.27B
$3.31B
$480M
$1.91B
Interest expense
-$407M
$0
$0
$0
-$485M
$0
$0
$0
Income before taxes
$4.09B
$3.24B
$1.47B
$3.11B
$1.77B
$2.97B
$175M
$1.68B
Income taxes
$770M
$561M
$384M
$919M
$460M
$509M
$99M
$461M
Net income
$3.32B
$2.68B
$1.09B
$2.2B
$1.31B
$2.46B
$76M
$1.22B
Net income attributable to common shareholders
$3.32B
$2.68B
$1.09B
$2.2B
$1.31B
$2.46B
$72M
$1.21B
EBITDA
$4.62B
$3.87B
$2.4B
$4.02B
$4.79B
$4.32B
$2.36B
$4.5B
Basic earnings per share
$1.62
$1.31
$0.53
$1.08
$0.64
$1.21
$0.04
$0.60
Diluted earnings per share
$1.62
$1.31
$0.53
$1.08
$0.64
$1.20
$0.04
$0.60
Recent news
Company coverage with links to the original publishers.
The global biotechnology market, valued at USD 2.02 trillion in 2026, is projected to reach USD 6.34 trillion by 2035 at a 13.61% CAGR. Leading biotech companies including Amgen, Gilead, Regeneron, Vertex, and Moderna reported strong Q3 2026 results with revenue growth ranging from 8% to 36%. The sector experienced record dealmaking activity with major acquisitions totaling tens of billions of dollars, driven by patent expiries, strong cash flows, and strategic pipeline expansion in oncology, immunology, and advanced therapies.
The article highlights five underrated dividend stocks offering attractive yields: Ares Capital (9.9% yield, 69 consecutive quarters of maintained/grown dividends), Bristol Myers Squibb (4% yield, 17 consecutive years of increases despite patent cliff concerns), Edison International (5.9% yield, 22 consecutive years of increases but facing wildfire litigation), MPLX LP (8.5% yield with 12.5% annual distribution growth), and NNN REIT (6% yield with 37 consecutive years of dividend increases, outperforming Realty Income).
The article examines five high-yield dividend stocks that appear riskier than they actually are. Pfizer and Bristol Myers Squibb face normal pharmaceutical industry headwinds from patent expirations but maintain sustainable dividends through strong cash flows. REITs Realty Income and W.P. Carey are pressured by rising interest rates, but historical market adjustments should protect profitability. Hormel Foods, despite slow turnaround progress, has strong financials and backing from the Hormel Foundation, making its dividend safer than its yield suggests.
Bristol Myers Squibb faces upcoming patent expirations on older drugs, particularly Eliquis losing U.S. patent protection in 2028. However, the company's newer growth portfolio is already generating $7.7 billion quarterly in revenue, exceeding the $5.42 billion from legacy drugs. With a 4% dividend yield and reasonable 55% payout ratio, the stock may appeal to aggressive income investors despite near-term patent cliff risks.
The article compares Amgen and Vertex Pharmaceuticals as investment options for 2027. Amgen offers diversified revenue streams across multiple drug franchises with lower valuation metrics but faces biosimilar competition and pricing pressures. Vertex demonstrates faster growth driven by cystic fibrosis dominance and promising pipeline candidates like Povetacicept, though at a premium valuation. The analyst recommends Vertex for long-term growth investors despite higher valuations, citing its superior growth trajectory and innovative pipeline.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
Ex-dividend
Amount / share
Pay date
Type
Oct 2, 2026
$0.63
Nov 2, 2026
recurring
Jul 2, 2026
$0.63
Aug 3, 2026
recurring
Apr 2, 2026
$0.63
May 1, 2026
recurring
Jan 2, 2026
$0.63
Feb 2, 2026
recurring
Oct 3, 2025
$0.62
Nov 3, 2025
recurring
Stock splits
Historical share-structure events and their execution dates.